Siva Ketha, MD
Interventional Cardiology · Raleigh, NCNPI 1164431284
Payments from drug & device makers
Across 124 payments — averaging $213.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$18K
- Teleflex LLC$3K
- Abbott$3K
- Shockwave Medical, Inc$538
- Boston Scientific$534
- Abiomed$269
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$9,80052%
- Travel & lodging$3,86620%
- Food & beverage$5,21328%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 17 | $17,727 |
| Teleflex LLC | 24 | $3,138 |
| Abbott | 8 | $2,796 |
| Shockwave Medical, Inc | 12 | $538 |
| Boston Scientific | 9 | $534 |
| Abiomed | 4 | $269 |
| Irhythm Technologies, Inc. | 7 | $266 |
| Cardiovascular Systems Inc. | 3 | $207 |
| Imperative Care, Inc | 2 | $189 |
| Sanofi-aventis U.S. LLC | 7 | $122 |
| Angiodynamics, Inc. | 3 | $88 |
| Asahi Intecc USA, Inc. | 1 | $79 |
| Philips North America LLC | 4 | $75 |
| Boehringer Ingelheim | 3 | $56 |
| Amgen | 3 | $49 |
| Pfizer | 2 | $44 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Novartis | 2 | $33 |
| Cardiva Medical, Inc. | 1 | $26 |
| AstraZeneca | 1 | $22 |
| Merck | 1 | $17 |
| Atricure, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Surmodics, Inc. | 1 | $17 |
| Cleerly, Inc. | 1 | $14 |
| Inari Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,432 in reported general payments places this provider in the 60th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 89 | $97,179 |
| XareltoRivaroxaban | 23 | $21,245 |
| EntrestoSacubitril/Valsartan | 19 | $20,862 |
| BrilintaTicagrelor | 26 | $14,455 |
| ClopidogrelClopidogrel Bisulfate | 246 | $2,129 |
| Metoprolol Succinate | 78 | $883 |
| Atorvastatin Calcium | 98 | $800 |
| Prasugrel Hcl | 28 | $695 |
| Rosuvastatin Calcium | 38 | $478 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 34 | $440 |
| Cilostazol | 39 | $438 |
| Carvedilol | 34 | $404 |
| Ezetimibe | 11 | $286 |
| Nitroglycerin | 39 | $275 |
| Amlodipine Besylate | 33 | $258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $44 | $97,17989 claims |
| NovartisEntresto | $33 | $20,86219 claims |
| AstraZenecaBrilinta | $22 | $14,45526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Raleigh
- Ravish SacharRaleigh$10.1M
- James ZidarRaleigh$1.1M
- Willis WuRaleigh$671K
- Robert JobeRaleigh$490K
- Dwijesh PatelRaleigh$445K
- Joel SchneiderRaleigh$361K
- Mohit PasiRaleigh$117K
- Deepak PasiRaleigh$115K
- Andrew SampsonRaleigh$95K
- Islam OthmanRaleigh$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.